FR2662352A1 - Gum-hygiene and health products based on elastin peptides - Google Patents
Gum-hygiene and health products based on elastin peptides Download PDFInfo
- Publication number
- FR2662352A1 FR2662352A1 FR9006517A FR9006517A FR2662352A1 FR 2662352 A1 FR2662352 A1 FR 2662352A1 FR 9006517 A FR9006517 A FR 9006517A FR 9006517 A FR9006517 A FR 9006517A FR 2662352 A1 FR2662352 A1 FR 2662352A1
- Authority
- FR
- France
- Prior art keywords
- hygiene
- health products
- peptides
- elastin
- gums according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 20
- 102000016942 Elastin Human genes 0.000 title claims abstract description 17
- 108010014258 Elastin Proteins 0.000 title claims abstract description 17
- 229920002549 elastin Polymers 0.000 title claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 9
- 102000035195 Peptidases Human genes 0.000 claims abstract description 5
- 108091005804 Peptidases Proteins 0.000 claims abstract description 5
- 239000004365 Protease Substances 0.000 claims abstract description 5
- 210000002808 connective tissue Anatomy 0.000 claims abstract description 5
- 210000004177 elastic tissue Anatomy 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- 229940051866 mouthwash Drugs 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 235000015278 beef Nutrition 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 abstract description 5
- 108010067372 Pancreatic elastase Proteins 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
PRODUITS D'HYGIENE ET DE SANTE POUR LES GENCIVES A BASE DE
PEPTIDES D'ELASTINE
La présente invention est relative à des produits d' hygi ène et de santé pour les gencives notamment pâte gingivale, bain de bouche, gel traitant ou autre, permettant de réaliser, corrélativement à une action de nettoyage ou de désinfection des gencives ou de la cavité buccale, une action efficace contre les élastases présentes au niveau de la gencive et qui conduisent généralement à une atrophie progressive et à un vieillissement du tissu conjonctif et, parfois à des manifestations inflammatoires souvent douloureuses.HYGIENE AND HEALTH PRODUCTS FOR GENDER-BASED
ELASTINE PEPTIDES
The present invention relates to hygiene and health products for the gums, in particular gingival paste, mouthwash, treating gel or the like, making it possible to carry out, correlatively to a cleaning or disinfecting action on the gums or the cavity. buccal, an effective action against the elastases present on the level of the gum and which generally lead to a progressive atrophy and to an aging of the connective tissue and, sometimes to inflammatory manifestations often painful.
On sait que les cellules musculaires lisses comme les cellules mésenchymateuses du genre des fibroblastes produisent naturellement des enzymes du genre. protéases et plus particulièrement du type élastases. La synthèse de ces enzymes augmente avec l'âge des individus et les conditions pathologiques éventuelles.On sait également que les élastases jouent un rôle important dans le déchaussement des dents de par leur action sur le tissu conjonctif qu' elles atrophient, cette action étant d'autant plus préjudiciable qu' à la production intrinsèque d' élastases par des cellules elles-memes, s' ajoutent souvent des infections locales, dues à des germes ou bactéries, capables également de produire de tels enzymes et d' attaquer les constituants des tissus conjonctifs. It is known that smooth muscle cells like mesenchymal cells of the fibroblast genus naturally produce enzymes of the genus. proteases and more particularly of the elastase type. The synthesis of these enzymes increases with the age of the individuals and the possible pathological conditions. We also know that elastases play an important role in the loosening of teeth by their action on the connective tissue that they atrophy, this action being d 'all the more harmful than the intrinsic production of elastases by cells themselves, are often added local infections, due to germs or bacteria, also capable of producing such enzymes and attacking the constituents of tissues conjunctives.
I1 s' avère donc particulièrement intéressant de pouvoir réaliser une inhibition efficace de 1' action de ces enzymes élastasiques et d'assurer ainsi un traitement amélioré des parodontopathies superficielles. It therefore turns out to be particularly advantageous to be able to effect effective inhibition of the action of these elastatic enzymes and thus to ensure an improved treatment of superficial periodontal diseases.
La présente invention a pour objet un produit d'hygiène et de santé gingivale qui répond à cet objectif de manière particulièrement intéressante, notamment quant à la permanence de son activité et à 1' efficacité des résultats obtenus contre 1' atrophie des gencives et les gingivites, et par suite sur les pertes dentaires qui en sont souvent la conséquence. The subject of the present invention is a gingival hygiene and health product which responds to this objective in a particularly advantageous manner, in particular as regards the permanence of its activity and the effectiveness of the results obtained against atrophy of the gums and gingivitis. , and consequently on the dental losses which are often the consequence.
A cet effet, les produits considérés, destines à limiter, voire à annihiler les effets des protéases de type élastasiques sur les tissus conjonctifs, se caractérisent en ce qu'ils comportent, en proportions et concentrations déterminées, des peptides d' élastine. To this end, the products under consideration, intended to limit, or even annihilate the effects of proteases of the elastatic type on the connective tissues, are characterized in that they contain, in determined proportions and concentrations, elastin peptides.
De préférence, les peptides d' élastine mis en oeuvre dans les produits considérés sont des peptides de type C 45, la concentration en peptides étant comprise entre 0,25 mg/ml et 20 mg/ml, et de préférence approximativement voisine de 2,5 mg/ml. Preferably, the elastin peptides used in the products under consideration are type C 45 peptides, the concentration of peptides being between 0.25 mg / ml and 20 mg / ml, and preferably approximately around 2, 5 mg / ml.
Avantageusement, les peptides présentent un poids moléculaire compris entre 5.000 et 150.000, et de préférence voisin de 45. 000. De préférence également, ces peptides sont réalisés à partir d'une hydrolyse de fibres élastiques provenant d'un prélèvement de nuque de boeuf et d' activité inhibitrice mesurée sur un substrat synthétique de séquence Suc (Ala) 3 pNA. Advantageously, the peptides have a molecular weight of between 5,000 and 150,000, and preferably close to 45,000. Preferably also, these peptides are produced from a hydrolysis of elastic fibers originating from a sample from the nape of the ox and of inhibitory activity measured on a synthetic substrate of sequence Suc (Ala) 3 pNA.
Des expérimentations ont été conduites par le
Professeur Ladislas ROBERT. Le tableau ci-après fournit les résultats d'expérimentations effectuées sur des prélèvements ou biopsies de gencives de sujets atteints de parodontopathies diverses, notamment de gingivites correspondant notamment aux stades 2 ou 3 de l'indice de
LOE et SILNESS (1963), confirmées par des photographies endobuccales, sans atteinte significative de l'os alvéolaire, 1' état pathologique ainsi constaté n'étant pas dû à une cause hormonale ou médicamenteuse susceptible de fausser la mesure.Experiments have been conducted by the
Professor Ladislas ROBERT. The table below provides the results of experiments carried out on samples or biopsies of gum tissue from subjects suffering from various periodontopathies, in particular gingivitis corresponding in particular to stages 2 or 3 of the index of
LOE and SILNESS (1963), confirmed by intraoral photographs, without significant damage to the alveolar bone, the pathological condition thus observed not being due to a hormonal or medicinal cause liable to distort the measurement.
Biopsie Concentration en peptides at élastine C 45
0 0,025 0,25 1 2,5 10 20
1- 0,832 0,777(7%) 0,399(52%) 0,250(70%) 0,050(941) 0,010(99%) 0,005(99)
2- 0,271 0,262(3%) 0,144(47%) 0,088(68%) 0,038(86%) 0,021(92%) 0,002(99%)
3- 0,450 0,040(11%) 0,027(40%) 0,021(53%) 0,016(64%) 0,015(67%) 0,007(82%)
4- 0,444 0,431(3%) 0,209(53%) 0,115(74%) 0,021(958) 0,003(99%) 0,0-lOt98%)
5- 0,384 0,357(7%) 0,190(51%) 0,092(75%) 0,017(96%) 0,012(97%) 0,014(96)
6- 0,184 0,175(5%) 0,93(49%) 0,068(63%) 0,011(94%) 0,003(99%) 0,001(99%)
Les chiffres donnés dans ce tableau fournissent, pour une série d'échantillons successifs, des résultats mesurant le taux en % dtinhibition de l'activité élestasique en fonction de la concentration en peptides de C 45, utilisant comme substrat le Suc (Ala) 3 pNA.Biopsy Concentration of peptides at elastin C 45
0 0.025 0.25 1 2.5 10 20
1- 0.832 0.777 (7%) 0.399 (52%) 0.250 (70%) 0.050 (941) 0.010 (99%) 0.005 (99)
2- 0.271 0.262 (3%) 0.144 (47%) 0.088 (68%) 0.038 (86%) 0.021 (92%) 0.002 (99%)
3- 0.450 0.040 (11%) 0.027 (40%) 0.021 (53%) 0.016 (64%) 0.015 (67%) 0.007 (82%)
4- 0.444 0.431 (3%) 0.209 (53%) 0.115 (74%) 0.021 (958) 0.003 (99%) 0.0-10% 98)
5- 0.384 0.357 (7%) 0.190 (51%) 0.092 (75%) 0.017 (96%) 0.012 (97%) 0.014 (96)
6 - 0.184 0.175 (5%) 0.93 (49%) 0.068 (63%) 0.011 (94%) 0.003 (99%) 0.001 (99%)
The figures given in this table provide, for a series of successive samples, results measuring the rate in% of inhibition of the elestastic activity as a function of the concentration of C 45 peptides, using as substrate Suc (Ala) 3 pNA .
On constate ainsi que le taux dtinhibition , qui s' élève déjà à 50 % environ pour une concentration en peptides de 0,25 mg/ml, atteint ou dépasse pratiquement 90 % pour une concentration de 2,5 mg/ml et s' approche de 99 % pour une concentration allant de 10 à 20 mg/ml. It can thus be seen that the inhibition rate, which already amounts to approximately 50% for a peptide concentration of 0.25 mg / ml, reaches or exceeds practically 90% for a concentration of 2.5 mg / ml and is approaching 99% for a concentration ranging from 10 to 20 mg / ml.
Il résulte des diverses expérimentations cliniques in vivo ainsi que des expériences in vitro que les nouvelles préparations à base de peptides d'élastine selon 1' invention sont très efficaces dans le traitement des parodontes en ce qu' elles inhibent de façon très importante l'activité élastasique. It follows from various clinical experiments in vivo as well as from in vitro experiments that the new preparations based on elastin peptides according to the invention are very effective in the treatment of periodonts in that they very significantly inhibit the activity elastatic.
A partir de des constatations, on a considéré selon la présente invention que l'apport par voie locale de ces préparations à base de peptides d' élastine, au tissu gingival, entrainerait une réduction des phénomènes inflammatoires. From observations, it has been considered according to the present invention that the local supply of these preparations based on elastin peptides, to the gum tissue, would lead to a reduction in inflammatory phenomena.
Selon la présente invention et à titre d' exemples indicatifs mais non limitatifs, on donne ci-après diverses formulations de produits d'hygiène incorporant des peptides d'élastine solutilisés dans des excipients appropriés et dont 1' activité sur les protéases élastasiques se révèle particulièrement efficace dans les conditions de l'utilisation de ces produits. According to the present invention and by way of indicative but nonlimiting examples, various formulations of hygienic products are given below incorporating elastin peptides used in suitable excipients and the activity of which on elastatic proteases is particularly revealed effective under the conditions of use of these products.
Exemple 1 - Pâte gingivale N 1
- Glycérine 5 %
- Sorbitol (70 %) 5 %
- Gel 1 %
- Conservateur 0,1 %
- Saccharinate de sodium 0,1
- Phosphate di cal ci que 37 %
- Laurylsulfate de sodium 1
- Diatami 15-40 microns 5 %
- Arôme 1 %
- Elastine 1 %
- Eau QSP 100 %
Exemple 2 - Pâte gingivale N 2
- Veegum 1 %
- Carboxyméthyl cellulose sodique 0, 5 %
- Glycérine 30 %
- Phosphate di cal cique 47 %
- Laurylsulfate de sodium 2 %
- Conservateur 0, 3 %
- Arôme 1 %
- Elastine 2
- Eau QSP 100 %
Exemple 3 - Gel gingival
- Hexamétaphosphate 0,20 %
- Phosphate disodique 0,10
- Saccharinate de sodium 0,02 %
- Carboxyméthyl cellulose sodique 0,55 %
- Silice liquide (Sident 22 S) 12,00 %
- Polyéthylène glycol (PEG 400) 3,50 %
- Sorbitol (70%) 68,00 %
- Conservateur 0,30 %
- Arôme 0,50 %
- Elastine 5,00 %
- Eau QSP 100 %
Exemple 4 - Bain de bouche
- Essence de menthe hydrosoluble 2,00 %
- Saccharinate de sodium 0, 50 %
- Huile de castor hydrogénéé
(Arlatone 975) 2,00 %
- Aromatisation menthe (Frescofor) 0, 50 %
- Conservateur (parahydroxybenzoate
de méthyle) 0,20 %
- Elastine 0, 50 %
- Eau QSP 100 % Example 1 - Gingival paste N 1
- Glycerin 5%
- Sorbitol (70%) 5%
- Gel 1%
- Preservative 0.1%
- Sodium saccharinate 0.1
- Phosphate di cal ci that 37%
- Sodium lauryl sulfate 1
- Diatami 15-40 microns 5%
- Aroma 1%
- Elastin 1%
- 100% QSP water
Example 2 - Gingival paste N 2
- Veegum 1%
- Carboxymethyl cellulose sodium 0.5%
- Glycerin 30%
- Calcium phosphate 47%
- Sodium lauryl sulfate 2%
- Preservative 0.3%
- Aroma 1%
- Elastin 2
- 100% QSP water
EXAMPLE 3 Gingival Gel
- Hexametaphosphate 0.20%
- Disodium phosphate 0.10
- 0.02% sodium saccharinate
- Carboxymethyl cellulose sodium 0.55%
- Liquid silica (Sident 22 S) 12.00%
- Polyethylene glycol (PEG 400) 3.50%
- Sorbitol (70%) 68.00%
- Preservative 0.30%
- Aroma 0.50%
- Elastin 5.00%
- 100% QSP water
Example 4 - Mouthwash
- Essence of water-soluble mint 2.00%
- Sodium saccharin 0.50%
- Hydrogenated beaver oil
(Arlatone 975) 2.00%
- Mint flavoring (Frescofor) 0, 50%
- Preservative (parahydroxybenzoate
methyl) 0.20%
- Elastin 0.50%
- 100% QSP water
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9006517A FR2662352B1 (en) | 1990-05-25 | 1990-05-25 | HYGIENE AND HEALTH PRODUCTS FOR GENCIVES BASED ON ELASTINE PEPTIDES. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9006517A FR2662352B1 (en) | 1990-05-25 | 1990-05-25 | HYGIENE AND HEALTH PRODUCTS FOR GENCIVES BASED ON ELASTINE PEPTIDES. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2662352A1 true FR2662352A1 (en) | 1991-11-29 |
| FR2662352B1 FR2662352B1 (en) | 1994-10-28 |
Family
ID=9396944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9006517A Expired - Fee Related FR2662352B1 (en) | 1990-05-25 | 1990-05-25 | HYGIENE AND HEALTH PRODUCTS FOR GENCIVES BASED ON ELASTINE PEPTIDES. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2662352B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119405788A (en) * | 2024-10-10 | 2025-02-11 | 湖北双星药业股份有限公司 | A pharmaceutical composition for preventing and treating gingival atrophy, and its preparation method and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2353282A1 (en) * | 1976-06-02 | 1977-12-30 | Invap Etablissement | APPLICATION OF ELASTIN AND ITS DERIVATIVES IN COSMETICS |
| JPS6289609A (en) * | 1985-10-16 | 1987-04-24 | Shiseido Co Ltd | Clear aqueous gel cosmetic |
| FR2618679A1 (en) * | 1987-07-30 | 1989-02-03 | Bonnaure Mallet Martine | Use of elastin for the preparation of a pharmaceutical composition which is useful in the treatment of periodontal disorders |
| JPH01283213A (en) * | 1988-05-09 | 1989-11-14 | Tadao Shiraishi | Toiletry product blended with enzyme |
-
1990
- 1990-05-25 FR FR9006517A patent/FR2662352B1/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2353282A1 (en) * | 1976-06-02 | 1977-12-30 | Invap Etablissement | APPLICATION OF ELASTIN AND ITS DERIVATIVES IN COSMETICS |
| JPS6289609A (en) * | 1985-10-16 | 1987-04-24 | Shiseido Co Ltd | Clear aqueous gel cosmetic |
| FR2618679A1 (en) * | 1987-07-30 | 1989-02-03 | Bonnaure Mallet Martine | Use of elastin for the preparation of a pharmaceutical composition which is useful in the treatment of periodontal disorders |
| JPH01283213A (en) * | 1988-05-09 | 1989-11-14 | Tadao Shiraishi | Toiletry product blended with enzyme |
Non-Patent Citations (2)
| Title |
|---|
| PATENT ABSTRACTS OF JAPAN, vol. 11, no. 297 (C-448)[2744], 25 septembre 1987; & JP-A-62 89 609 (SHISEIDO CO.) 24-04-1987 * |
| PATENT ABSTRACTS OF JAPAN, vol. 14, no. 57 (C-684)[4000], 2 février 1990; & JP-A-01 283 213 (TADAO SHIRAISHI) 14-11-1989 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119405788A (en) * | 2024-10-10 | 2025-02-11 | 湖北双星药业股份有限公司 | A pharmaceutical composition for preventing and treating gingival atrophy, and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2662352B1 (en) | 1994-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Quirynen et al. | The rôle of chlorhexidine in the one‐stage full‐mouth disinfection treatment of patients with advanced adult periodontitis: Long‐term clinical and microbiological observations | |
| Quirynen et al. | One stage full‐versus partial‐mouth disinfection in the treatment of chronic adult or generalized early‐onset periodontitis. II. Long‐term impact on microbial load | |
| Bollen et al. | Full‐versus partial‐mouth disinfection in the treatment of periodontal infections: A pilot study: long‐term microbiological observations | |
| RU2355420C2 (en) | Toothpaste containing lactulose, betaine, chondroitin sulphate and enzymes: papain, lysocim, ribonuclease and lidase | |
| RU2381021C2 (en) | Liposome containing tooth paste | |
| Quirynen et al. | The effect of periodontal therapy on the number of cariogenic bacteria in different intra‐oral niches | |
| Jalaluddin et al. | Antimicrobial activity of Curcuma longa L. extract on periodontal pathogens | |
| CN1461209A (en) | Use of olive oil in preparation of products for oral hygiene for eliminating or reducing bacterial plaque and/or bacteria in mouth | |
| RU2494724C2 (en) | Toothpaste, containing freeze-dried mass of live bifidobacteria | |
| RU2496468C2 (en) | Tooth paste containing mixed bacterial lysate | |
| JP3207912B2 (en) | Collagenase activity inhibitor | |
| Daly et al. | Cementum involved in periodontal disease: a review of its features and clinical management | |
| RU2293551C1 (en) | Composition for mouth cavity disease prophylaxis | |
| US10918620B2 (en) | Use of statins for periodontal disease and bone regeneration | |
| FR2915386A1 (en) | USE OF AQUEOUS EXTRACT OF GRAPE PEPINS IN ASSOCIATION WITH AT LEAST ONE FLUOR SALT AGAINST THE FORMATION OR ACCUMULATION OF DENTAL BIOFILM AND THE COMPOSITIONS COMPRISING SAID ASSOCIATION | |
| FR2662352A1 (en) | Gum-hygiene and health products based on elastin peptides | |
| Mani et al. | Clinical and microbiological evaluation of chlorine dioxide based mouthwash and toothpaste in periodontitis patients along with combination of nutritional dietary supplement of CoQ10 | |
| Pasiga et al. | Clinical effects of alkaline ionization water (AIW) as a mouthwash against the reduction of dental plaque | |
| CN103690452B (en) | Composition and method for preventing and treating oral diseases | |
| JP2003176225A (en) | Composition for oral cavity and external use for skin | |
| JPH04290819A (en) | Collagenase activity inhibitor | |
| JP5294536B2 (en) | Gingival epithelial cell spreading inhibitor | |
| Seyam et al. | Evaluation of the effect of fluoride application on periodontal health during orthodontic treatment (A clinical study) | |
| Sköld-Larsson et al. | Effect of a triclosan-containing dental gel on the levels of prostaglandin I2 and interleukin-1 β in gingival crevicular fluid from adolescents with fixed orthodontic appliances | |
| Pandia et al. | The differences in the effects of propolis, sodium hypochlorite, and EDTA as an irrigant solutions on the microhardness of root canal dentin: In-vitro study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SN | Distraint notified (in the national patent register) | ||
| ST | Notification of lapse |